Nicotine and Non-nicotine Smoking Cessation Pharmacotherapies
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Cigarette smoking remains an important risk factor for premature cardiovascular disease and its complications. There are clear benefits of cigarette smoking cessation on the rate of clinical outcomes, and in addition to behavioral therapies, various pharmacologic strategies have been developed to help achieve this goal. First-line therapies include nicotine replacement and/or bupropion. Second-line treatments include clonidine and nortriptyline. Additional treatment strategies, with less proven efficacy, include monoamine oxidase inhibitors, selective serotonin reuptake inhibitors, opioid receptor antagonists, bromocriptine, antianxiety drugs, nicotinic receptor antagonists (eg, mecamylamine), and glucose tablets. Various approaches under investigation include the use of partial nicotine agonists (eg, varenicline), inhibitors of the hepatic P-450 enzyme (eg, methoxsalen), cannaboid-1 receptor antagonists (eg, rimonabant), and nicotine vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality: A Randomized Clinical Trial
Anthonisen, N. R., Skeans, M. A., Wise, R. A., Manfreda, J., Kanner, R. E., Connett, J. E., & for the Lung Health Study Research Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-4-200502150-00005 · Cited by 1,237
The endocannabinoid system and its therapeutic exploitation
Marzo, V. D., Bifulco, M., & Petrocellis, L. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1495 · Cited by 1,090
Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors
McGehee, D. S., Heath, M. J. S., Gelber, S., Devay, P., & Role, L. W. (1995) · Science · doi:10.1126/science.7569895 · Cited by 1,070 · cited 1×
“Nicotine binds stereospecifically to acetylcholine receptors in autonomic ganglia in the adrenal medulla, at neuromuscular junctions, and in the brain.(58) It can produce an increase in alertness and cognitive performance by stimulating the cortex through the locus ceruleus.”
BackgroundNicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
Cardiovascular complications of cocaine use
Lange, R. A., & Hillis, L. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108023450507 · Cited by 810
Passive smoking and the risk of coronary heart disease—a meta-analysis of epidemiologic studies
He, J., Vupputuri, S., Allen, K., Prerost, M. R., Hughes, J., & Whelton, P. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401204 · Cited by 616
The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease
Joseph, A. M., Norman, S. M., Ferry, L. H., Prochazka, A. V., Westman, E. C., Steele, B. G., Sherman, S. E., Cleveland, M., Antonuccio, D. O., Hartman, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352402 · Cited by 492
The Influence of Smoking Cessation on the Prevalence of Overweight in the United States
Flegal, K. M., Troiano, R. P., Pamuk, E. R., Kuczmarski, R. J., & Campbell, S. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331801 · Cited by 482 · cited 1×
“In addicted patients, withdrawal from nicotine is characterized by craving, nervousness, restlessness, irritability, anxiety, mood lability, sleep disturbance, drowsiness, impaired concentration, increased appetite, weight gain, blood pressure elevations, and minor somatic complaints.(72,73) In most smokers, the habit…”
BackgroundCohen, C., Perrault, G., Voltz, C., Steinberg, R., & Soubrié, P. (2002) · Behavioural Pharmacology · doi:10.1097/00008877-200209000-00018 · Cited by 396
Cited by
Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers
McKee, S. A., Harrison, E. L. R., O'Malley, S. S., Krishnan-Sarin, S., Shi, J., Tetrault, J. M., Picciotto, M. R., Petrakis, I. L., Estevez, N., & Balchunas, E. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.01.029 · Cited by 298
Bupropion improves attention but does not affect impulsive behavior in healthy young adults.
Acheson, A., & de Wit, H. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.16.2.113 · Cited by 82
Varenicline ameliorates nicotine withdrawal-induced learning deficits in C57BL/6 mice.
Raybuck, J. D., Portugal, G. S., Lerman, C., & Gould, T. J. (2008) · Behavioral Neuroscience · doi:10.1037/a0012601 · Cited by 62
A Longer Course of Varenicline Therapy Improves Smoking Cessation Rates
Lee, J. H., Jones, P. G., Bybee, K., & O’Keefe, J. H. (2008) · Preventive Cardiology · doi:10.1111/j.1751-7141.2008.00003.x · Cited by 34
Metadata
- Authors
- Frishman, W. H., Mitta, W., Kupersmith, A., & Ky, T.
- Venue
- Cardiology in Review
- Published
- 2006-03
- Volume
- 14
- Issue
- 2
- Pages
- 57-73
- ISSN
- 1061-5377 (ISSN-L)
- OpenAlex
- W2058218561
- Cited by
- 50
- References
- 27
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nicotine and Non-nicotine Smoking Cessation Pharmacotherapies. https://app.cochat.ai/papers/10.1097/01.crd.0000172309.06270.25
- The paper
- Frishman, W. H., Mitta, W., Kupersmith, A., & Ky, T. (2006). Nicotine and Non-nicotine Smoking Cessation Pharmacotherapies. Cardiology in Review. https://doi.org/10.1097/01.crd.0000172309.06270.25
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.